---
trial_id: 1006
discovery_date: 2022-06-24 12:35:36.845109
date: 2022-06-24 12:35:36.845109
title: "A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea&#x2F;Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive ..."
summary: |
  
link: 'https://www.novartis.com//clinicaltrials/study/nct03474965'
published_date: NaT
trial_source: Novartis
relevant: 
options:
  unlisted: false
---
